Track topics on Twitter Track topics that are important to you
Rare disease play True North Therapeutics Inc. (South San Francisco, Calif.) raised $45 million in a series D round led by new investors HBM Healthcare Investments and Redmile Group and existing investor Perceptive Advisors. New investor Franklin Templeton Investments and undisclosed existing investors also participated.
The company's TNT009, a humanized mAb against complement component 1 s subcomponent (C1S), is in Phase Ib testing to treat complement-mediated diseases including cold agglutinin disease (CAD), bullous pemphigoid, warm autoimmune hemolytic anemia and end-stage renal disease (ESRD) (see BioCentury, April 21, 2014).
The mAb has Orphan Drug designation in the U.S. and EU for autoimmune hemolytic anemia, a group of blood disorders that includes CAD.
In June, True North announced interim Phase Ib data that showed three of five CAD patients treated with TNT009 had a complete response after the four-week dosing period. Furthermore, three patients who were transfusion-dependent at baseline became transfusion-independent during treatment, and two who had been treated chronically with steroids became steroid-free during treatment. The data were presented at the European Hematology Association meeting in Copenhagen.
CEO Nancy Stagliano said the new round will support further development of TNT009 and a preclinical next-generation mAb against C1S. She declined to disclose development timelines.
Original Article: True North raises $45M series DNEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...